InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (7 ops.)
Discover the detailed record of transactions filed by Watanabe Todd Franklin, President and Chief Executive Officer. Director active across 1 companies, notably Arcutis Biotherapeutics, Inc.. Cumulatively, 34 reports have been published. Total volume traded: €185k. The latest transaction was disclosed on 6 June 2022 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations34 total
€19,7021,000 shares@ €19.70180.0007% mcap8.5% of flow
Common Stock
SEC:0001567619-22-012377:0·
€20,6461,000 shares@ €20.64570.0008% mcap8.9% of flow
Common Stock
SEC:0001567619-22-009639:0·
€19,6491,000 shares@ €19.6490.0007% mcap8.5% of flow
Common Stock
SEC:0001567619-22-008131:0·
€4,680300 shares@ €15.59890.0002% mcap2.0% of flow
Common Stock
SEC:0000899243-22-010801:0·
070,900 shares0
Common Stock
SEC:0001567619-22-006498:0·
€34,0782,153 shares@ €15.82810.0013% mcap14.8% of flow
Common Stock
SEC:0001567619-22-006230:0·
€1,4711,000 shares@ €1.47150.0001% mcap2.2% of flow
Common Stock
SEC:0001567619-22-003692·
€1,4711,000 shares@ €1.47150.0001% mcap0.6% of flow
Common Stock
SEC:0001567619-22-003692:0·
€1,4891,000 shares@ €1.48940.0001% mcap2.3% of flow
Common Stock
SEC:0001567619-22-000851·
€1,4891,000 shares@ €1.48940.0001% mcap0.6% of flow
Common Stock
SEC:0001567619-22-000851:0·
€1,4901,000 shares@ €1.49040.0001% mcap2.3% of flow
Common Stock
SEC:0001567619-21-021900·
€1,4901,000 shares@ €1.49040.0001% mcap0.6% of flow
Common Stock
SEC:0001567619-21-021900:0·
€1,4541,000 shares@ €1.45440.0001% mcap2.2% of flow
Common Stock
SEC:0001567619-21-019584·
€1,4541,000 shares@ €1.45440.0001% mcap0.6% of flow
Common Stock
SEC:0001567619-21-019584:0·
€3,6232,500 shares@ €1.44930.0001% mcap5.5% of flow
Common Stock
SEC:0001567619-21-018022·
€3,6232,500 shares@ €1.44930.0001% mcap1.6% of flow
Common Stock
SEC:0001567619-21-018022:0·
€2,1781,500 shares@ €1.4520.0001% mcap3.3% of flow
Common Stock
SEC:0001567619-21-017895·
€2,1781,500 shares@ €1.4520.0001% mcap0.9% of flow
Common Stock
SEC:0001567619-21-017895:0·
€1,4191,000 shares@ €1.4190.0001% mcap2.1% of flow
Common Stock
SEC:0001567619-21-016925·
€1,4191,000 shares@ €1.4190.0001% mcap0.6% of flow
Common Stock
SEC:0001567619-21-016925:0·
€1,4201,000 shares@ €1.41990.0001% mcap2.2% of flow
Common Stock
SEC:0001567619-21-014784·
€1,4201,000 shares@ €1.41990.0001% mcap0.6% of flow
Common Stock
SEC:0001567619-21-014784:0·
€2,4871,750 shares@ €1.42130.0001% mcap3.8% of flow
Common Stock
SEC:0001567619-21-013157·
€2,4871,750 shares@ €1.42130.0001% mcap1.1% of flow
Common Stock
SEC:0001567619-21-013157:0·
07,377 shares0
Common Stock
SEC:0001567619-21-012499·
25 of 34 declarations
About Watanabe Todd Franklin
Todd Franklin Watanabe is a biopharmaceutical executive best known for serving as President and Chief Executive Officer of Arcutis Biotherapeutics, Inc., where he has held senior leadership responsibilities since the company’s early years. According to Arcutis’ leadership biography, he joined the company as President in 2016 and became Chief Executive Officer in 2017. His career has focused on corporate strategy, business development, operational execution, and the commercialization of medical dermatology products. At Arcutis, he has helped shape the company’s positioning as a dermatology-focused innovator addressing unmet needs for patients and healthcare professionals. ([arcutis.com](https://www.arcutis.com/leadership/frank-watanabe/?utm_source=openai)) Before joining Arcutis, Watanabe was co-founder and Chief Operating Officer of Kanan Therapeutics, a cardiovascular drug development company. He also served as Vice President of Strategy and Corporate Development at Kythera Biopharmaceuticals, reflecting a strong background in corporate planning and portfolio development. His earlier executive experience includes leadership roles at Amgen, where he was involved in the development of Repatha for hyperlipidemia and Aimovig for migraine, as well as the U.S. marketing of Enbrel in dermatology and rheumatology. Prior to that, he held executive positions at Eli Lilly and Company and served in a U.S. government role. ([arcutis.com](https://www.arcutis.com/leadership/frank-watanabe/?utm_source=openai)) Watanabe’s profile is further distinguished by extensive experience in highly regulated, global healthcare environments and by 25 years of service as a commissioned officer in the U.S. Navy Reserve. He also formerly served on the board of Amunix Pharmaceuticals. Academically, he earned both a BA in international relations and an MA in national security studies from Georgetown University. Overall, his background combines biotechnology leadership, strategic growth expertise, governance experience, and commercial execution—an especially relevant combination for a publicly traded U.S. life sciences company such as Arcutis. ([arcutis.com](https://www.arcutis.com/leadership/frank-watanabe/?utm_source=openai))
